Tyra Biosciences, Inc. (TYRA) research
Tyra Biosciences, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $22.41
- As of
Tyra Biosciences, Inc. (TYRA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-15.
As of . Source: SEC EDGAR filings for TYRA. Method and limitations.
Share the TYRA intelligence card
See TYRA live in the terminal
Track TYRA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live TYRA terminal, freeActive signals for TYRA
- highCONSENSUS_BUY
3 tracked funds increased TYRA this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased TYRA this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +344% to TYRA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2126% to TYRA (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in TYRA
FREE, NO ACCOUNT
Every signal on TYRA, as it fires
You are seeing 5 of 27 signals recorded on TYRA since 2026-05-31.
The five above landed across 2 days. The other 22 were recorded on 3 other days. 19 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TYRA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 90240B106 · 2026Q2 | $14.4M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 90240B106 · 2026Q2 | $8.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 90240B106 · 2026Q2 | $5.7M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 90240B106 · 2026Q2 | $645K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TYRA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TYRA against its peers
TYRA's return on equity of -46.3% ranks in the 40th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | TYRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 74.7M | n/a | 17 |
| Operating margin | n/a | -145.0% | n/a | 18 |
| Net margin | n/a | -106.4% | n/a | 19 |
| Return on equity | -46.3% | -35.1% | 40 | 20 |
Peers (22): NTLA, NBTX, LKFT, SEPN, BHVN, STOK, RXRX, ABSI, ZYME, TSHA, IMCR, XNCR, NVAX, FBRX, ANAB, GHRS, SNDX, INBX, VIR, MESO, AGIO, ADMA. Left out: KARD (no annual filing), KLRA (no annual filing), COAG (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TYRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TYRA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TYRAand get the insider, 13F, options, and confluence read in one view.